FOLEY HOAG LLP for GILEAD SCIENCES INC
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL KIM | — |
Medicare/Medicaid MMM
Ryn White Care Act reauthorization; Hepatitis C (HCV) policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV testing, screening, and linkage to care programs; HR 2430 and S.934, FDA Reauthorization Act. Federal program coverage; access and reimbursement issues for Hep C, HIV, and oncology products. Coverage of pharmaceuticals, cost-sharing, and other access issues; Implementation of Pub. L. No. 111-148; issues related to coverage and reimbursement of pharmaceuticals; FDA issues and 340B.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL KIM | — |
Pharmacy PHA
Coverage of pharmaceuticals, cost-sharing, and other access issues, HR 2430 and S.934, FDA Reauthorization Act; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; issues related to coverage and reimbursement of pharmaceuticals; issues related to Medicare, Medicaid, and ACA implementation; FDA issues and 340B.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL KIM | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.